LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced, that Jim Clemmer, President and Chief Executive Officer, will present at the Leerink Partners Global Healthcare Conference on Monday, Mar. 9, 2026. The Company's presentation will begin at 1:40 p.m. (ET). A live we. ...

Key Takeaways AngioDynamics expanded EU NanoKnife use to liver, pancreas, kidney and prostate tumors.ANGO will launch the LIVER-IRE Global Registry to assess real-world liver tumor outcomes.Europe drives 28% of global IRE volumes, supporting NanoKnife's multi-organ growth strategy.AngioDynamics (ANGO) recently announced expanded indications in Europe for its NanoKnife System, broadening its clinical utility in soft tissue tumor ablation. The expanded approval covers NanoKnife’s use for soft tissue ablation ...

Shares of AngioDynamics (ANGO) have gained 0.1% over the past four weeks to close the last trading session at $10.06, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $19.33 indicates a potential upside of 92.2%.The average comprises three short-term price targets ranging from a low of $16.00 to a high of $24.00, with a standard deviation of $4.16. While the lowest estimate indic ...

Core Viewpoint - AngioDynamics reported a breakeven adjusted earnings per share for Q2 fiscal 2026, showing improvement from a loss in the previous year, but the stock has underperformed the S&P 500 recently, raising questions about its future performance leading up to the next earnings release [2][1]. Financial Performance - The company achieved pro-forma revenues of $79.4 million in Q2, an 8.8% increase year over year, surpassing the Zacks Consensus Estimate by 4.5% [4]. - U.S. net revenues were $67.6 million, reflecting a 7.8% year-over-year increase, exceeding the estimate of $62.3 million [5]. - Pro-forma international revenues reached $11.8 million, up 8.8% from the previous year, also surpassing projections [5]. Segment Analysis - The Med Tech segment reported pro-forma net sales of $35.7 million, a 13% increase year over year, exceeding the estimate of $32.7 million [6]. - Key drivers included Auryon sales of $16.3 million (up 18.6% year over year) and Mechanical Thrombectomy revenues of $11 million (up 3.9% year over year) [7]. - Pro-forma Med Device revenues totaled $43.8 million, a 5.6% increase from the prior year, also above projections [8]. Margin and Expenses - Pro-forma gross profit increased by 14% to $44.8 million, with gross margin expanding by 170 basis points to 56.4%, surpassing the projected margin of 54.2% [9]. - Sales and marketing expenses rose 4.4% to $26.7 million, while R&D expenses increased by 20.7% to $7.8 million [10]. Cash Position - At the end of Q2 fiscal 2026, AngioDynamics had cash and cash equivalents of $41.6 million, up from $38.8 million at the end of Q1, with no debt on the balance sheet [11]. Guidance and Outlook - The company updated its fiscal 2026 guidance, expecting net sales between $312 million and $314 million, an increase from previous guidance [12]. - Med Tech revenue growth is projected at 14-16%, while Med Device growth is expected to be flat to 1% [13]. - The adjusted loss per share is anticipated to be between 33 cents and 23 cents, with the consensus estimate at a loss of 28 cents [14]. - Estimates have trended downward recently, with a significant revision of -31.25% [15].

Core Viewpoint - AngioDynamics (ANGO) has shown a downtrend recently, losing 6.1% over the past week, but a hammer chart pattern suggests a potential trend reversal due to increased buying interest [1][2]. Technical Analysis - The hammer chart pattern indicates a possible bottom in the stock price, suggesting that selling pressure may be exhausting [2][5]. - This pattern forms when there is a small candle body with a long lower wick, indicating that despite a downtrend, buyers are starting to emerge [4][5]. - Hammer candles can appear on various timeframes and are used by both short-term and long-term investors [5]. Fundamental Analysis - There has been a positive trend in earnings estimate revisions for ANGO, with a 3.6% increase in the consensus EPS estimate over the last 30 days, indicating analysts expect better earnings [7][8]. - ANGO holds a Zacks Rank of 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks, which typically outperform the market [9][10]. - The Zacks Rank serves as a timing indicator, suggesting that the company's prospects are improving, further supporting the potential for a turnaround [10].

Core Insights - AngioDynamics (ANGO) is experiencing growth driven by its NanoKnife product and a focus on cancer treatment markets, supported by a strong second-quarter fiscal 2026 performance and ongoing studies [1][2] Financial Performance - AngioDynamics reported a revenue increase of 8.8% year over year to $79.4 million in fiscal Q2 2026, with the NanoKnife revenue rising 22.2% due to record prostate cancer procedure volumes [7][10] - The Auryon franchise generated $16.3 million in revenue, reflecting an 18.6% year-over-year growth, marking 18 consecutive quarters of double-digit growth [5][10] - The company has a market capitalization of $422.1 million and projects a 51.9% growth over the next year [2] Growth Drivers - The NanoKnife franchise is a key growth driver, with probe sales increasing 14.4% year over year, attributed to rising adoption in prostate cancer procedures [3][4] - Management noted steady adoption of NanoKnife, supported by procedural growth and increasing clinical utilization, particularly in the prostate cancer market [4] - The mechanical thrombectomy portfolio saw a revenue increase of 3.9% year over year to $11 million, with AlphaVac achieving over 40% growth [9] Market Position and Trends - AngioDynamics has gained 9.8% in share price over the last six months, outperforming the industry growth of 5.2% and the S&P 500's increase of 11.9% [1] - The company has been experiencing a positive estimate revision trend, with the Zacks Consensus Estimate for loss narrowing to 27 cents per share for fiscal 2026 [13] Challenges - Management acknowledged ongoing tariff-related costs of $4–$6 million for the fiscal year, which may pose a structural margin headwind [11][12]

Core Viewpoint - AngioDynamics has undergone a significant transformation over the past five years, shifting from a focus on interventional radiology to a more scientifically-driven portfolio aimed at larger, addressable markets [3]. Company Transformation - The company started as an interventional radiology-based entity in upstate New York, building a strong legacy within that community [3]. - Over the last five years, AngioDynamics has focused on refreshing its portfolio, which included three divestitures to exit certain markets [4].

Group 1 - The article does not provide any relevant content regarding the company or industry [1]

Core Insights - AngioDynamics is experiencing significant growth in its MedTech portfolio, particularly with the Auryon platform, which has generated over $60 million in revenue this year, up from zero at launch in September 2020 [1][4] - The company is transitioning from a legacy interventional radiology focus to a more science-driven MedTech portfolio, targeting larger and faster-growing markets [2][3] - CEO Jim Clemmer plans to retire later this year but will remain involved as a major shareholder and advisor during the leadership transition [4][17] Product and Market Developments - Auryon, a laser-based atherectomy platform, has seen nearly 20% growth year-to-date, with increased traction in hospitals and higher average selling prices [5] - The AlphaVac system, targeting pulmonary embolism, is positioned as a differentiated product in the VTE market, which is still early in its penetration curve, with only about 15% market penetration [6][7] - NanoKnife, used for treating intermediate-risk prostate cancer, has received an on-label indication and is expected to expand into benign prostatic hyperplasia (BPH) [8][9][16] Financial Performance and Projections - AngioDynamics is debt-free with positive adjusted EBITDA and expects to be cash-flow positive by fiscal 2026, with MedTech products projected to exceed 50% of revenue by fiscal 2027 [4][11][14] - The company's MedTech products have achieved a 25% compound annual growth rate over the past five years, with continued growth anticipated [10][11] - Management plans to optimize the portfolio further as MedTech becomes a larger share of the business, with no substantial M&A expected in the near term [13][14] Leadership Transition - The company will conduct a deliberate search for a new CEO, considering both internal and external candidates, with no rush to finalize the appointment [17][18] - Clemmer's retirement is based on personal circumstances, and he feels confident in the company's recent execution and results [17][18]

Summary of AngioDynamics FY Conference Call (January 14, 2026) Company Overview - **Company**: AngioDynamics (NasdaqGS: ANGO) - **Industry**: Medical Technology (MedTech) and Medical Devices - **Transformation**: Over the past five years, AngioDynamics has shifted from an interventional radiology-based company to a more diversified MedTech portfolio, focusing on larger, addressable markets [2][3] Key Points and Arguments Portfolio Transformation - The company has undergone significant transformation, divesting from slow or undifferentiated markets to focus on a scientific-based MedTech portfolio [3][4] - Achieved a five-year compound annual growth rate (CAGR) of approximately 25% in MedTech markets during this transformation [4] Operating Segments - AngioDynamics operates in two segments: - **MedTech Portfolio**: Focused on growth and innovation - **MedDevice Portfolio**: Represents legacy products that are still generating revenue [5] Focus Areas - The company targets two major disease states: cardiovascular disease and solid tumor cancer, which are leading causes of mortality globally [5][6] Product Highlights - **Auryon**: Launched in September 2020, this product has generated over $60 million in revenue in its second year, capturing market share from major competitors [7][8] - **AlphaVac**: A new product for treating pulmonary embolism (PE), designed to safely remove clots from patients [10][11] - **NanoKnife**: A device for treating intermediate-risk prostate cancer, recently received FDA clearance and CPT-1 code for reimbursement [19][21] Market Potential - The prostate cancer market is significant, with 300,000 diagnoses expected in the U.S. this year, and nearly half classified as intermediate risk [19] - The benign prostatic hyperplasia (BPH) market is larger than the prostate cancer market, presenting further growth opportunities [26] Financial Performance - The company is transitioning to positive EBITDA and cash flow, with zero debt on the balance sheet [29][42] - Recent financial results exceeded Wall Street expectations, with guidance raised in several categories [30][42] Future Growth Strategy - AngioDynamics plans to leverage existing technologies to expand into new markets without relying heavily on M&A [47][50] - The company aims to increase its market presence in thrombectomy and coronary markets, which are larger than current markets [39][40][41] Management Transition - CEO Jim Clemmer announced his retirement, which may have impacted stock performance, but he expressed confidence in the company's future [32][53] Additional Important Information - The company has been recognized by Time Magazine as one of the top 25 medical inventions, highlighting the innovative nature of its products [24] - AngioDynamics is focusing on education and awareness campaigns to promote its new treatment options, particularly NanoKnife [22][23] This summary encapsulates the key points discussed during the AngioDynamics FY Conference Call, highlighting the company's strategic transformation, product innovations, market opportunities, and financial outlook.